Dl-Alpha-Tocopherol

This article discusses two clinical trials investigating the use of Dl-Alpha-Tocopherol, also known as vitamin E, in treating Alzheimer’s disease and preventing atherosclerosis. These studies aim to evaluate the potential benefits of vitamin E supplementation in slowing disease progression and improving patient outcomes.

Table of Contents

What is DL-Alpha-Tocopherol?

DL-Alpha-Tocopherol, commonly known as Vitamin E, is a fat-soluble vitamin that acts as an antioxidant in the body[2]. It is available as a dietary supplement and is also used in clinical trials to investigate its potential health benefits. The “DL” prefix indicates that this is a synthetic form of Vitamin E[2].

Medical Conditions Treated

Research suggests that DL-Alpha-Tocopherol may be beneficial in treating or preventing the following conditions:

  • Atherosclerosis: This is a condition where arteries become hardened and narrowed due to the buildup of plaque. Studies are investigating whether Vitamin E can slow down the progression of early atherosclerosis[1].
  • Alzheimer’s Disease: Researchers are exploring the potential of Vitamin E to slow down the progression of Alzheimer’s disease, a neurodegenerative disorder that affects memory and cognitive function[2].

Dosage and Administration

The dosage of DL-Alpha-Tocopherol can vary depending on the condition being treated and the specific study protocol. In the clinical trials reviewed:

  • For atherosclerosis prevention: 400 IU (International Units) per day was used[1].
  • For Alzheimer’s disease: 2,000 IU per day, given as 1,000 IU twice daily (morning and evening)[2].

It’s important to note that these dosages are specific to clinical trials and may not be appropriate for general use. Always consult with a healthcare provider before starting any new supplement regimen.

How It Works

DL-Alpha-Tocopherol is believed to work through several mechanisms:

  • Antioxidant effects: As an antioxidant, it helps protect cells from damage caused by free radicals, which are unstable molecules that can harm cellular structures[2].
  • Neuroprotection: In Alzheimer’s disease, it may help protect brain cells from damage, potentially slowing the progression of the disease[2].
  • Cardiovascular health: In atherosclerosis, it may help reduce the progression of plaque buildup in arteries[1].

Current Research

Several clinical trials are investigating the potential benefits of DL-Alpha-Tocopherol:

  • VEAPS (Vitamin E Atherosclerosis Prevention Study): This study is examining whether Vitamin E supplementation can reduce the progression of early atherosclerosis in healthy individuals over 40 years of age with elevated LDL cholesterol levels[1].
  • TEAM-AD (Trial of Vitamin E and Memantine in Alzheimer’s Disease): This study is investigating whether Vitamin E, alone or in combination with memantine (another Alzheimer’s medication), can slow the progression of Alzheimer’s disease in patients with mild to moderate dementia[2].

Potential Side Effects

While the clinical trials reviewed did not specifically mention side effects, it’s important to note that high doses of Vitamin E can potentially cause adverse effects. These may include:

  • Increased risk of bleeding
  • Nausea and diarrhea
  • Headache
  • Fatigue

As with any supplement or medication, it’s crucial to discuss potential risks and benefits with a healthcare provider before starting DL-Alpha-Tocopherol supplementation.

Aspect Alzheimer’s Disease Trial Atherosclerosis Prevention Study
Drug Name Dl-Alpha-Tocopherol (Vitamin E) Dl-Alpha-Tocopherol (Vitamin E)
Dosage 2,000 IU per day 400 IU per day
Study Duration 1 to 4 years 3 years
Primary Outcome Change in ADCS/ADL Inventory Change in carotid artery IMT
Target Population Mild to moderately demented Alzheimer’s patients Healthy individuals over 40 with high LDL cholesterol
Other Interventions Memantine, combination therapy None

Ongoing Clinical Trials on Dl-Alpha-Tocopherol

  • Study on the Early Use of Levosimendan Compared to Placebo for Patients with Cardiogenic Shock

    Recruiting

    3 1 1
    Investigated diseases:
    France
  • Study on the Effects of Levosimendan for Patients with Cardiogenic Shock Being Weaned from ECMO

    Recruiting

    2 1 1
    Investigated diseases:
    Austria

Glossary

  • Dl-Alpha-Tocopherol: A synthetic form of vitamin E used in clinical trials for its potential neuroprotective and antioxidant properties.
  • Alzheimer's Disease: A progressive brain disorder that affects memory, thinking skills, and the ability to carry out simple tasks.
  • Atherosclerosis: A condition where arteries become hardened and narrowed due to the buildup of plaque, increasing the risk of heart disease and stroke.
  • Memantine: A medication used to treat moderate to severe Alzheimer's disease, which works by regulating glutamate activity in the brain.
  • Intima-Media Thickness (IMT): A measurement of the thickness of the inner two layers of the carotid artery wall, used as an indicator of atherosclerosis progression.
  • LDL Cholesterol: Low-density lipoprotein cholesterol, often called 'bad' cholesterol, which can contribute to plaque buildup in arteries.
  • ADCS/ADL Inventory: Alzheimer's Disease Cooperative Study/Activities of Daily Living Inventory, a tool used to assess functional abilities in Alzheimer's patients.
  • MMSE: Mini-Mental State Examination, a brief test used to assess cognitive impairment in patients.
  • ADAS-cog: Alzheimer's Disease Assessment Scale – Cognitive Subscale, a test designed to measure cognitive function in Alzheimer's patients.
  • Neuropsychiatric Inventory (NPI): A tool used to assess psychological and behavioral problems in patients with dementia.

References

  1. https://clinicaltrials.gov/study/NCT00114387
  2. https://clinicaltrials.gov/study/NCT00235716